{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T09:06:42Z","timestamp":1770282402361,"version":"3.49.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103733"],"award-info":[{"award-number":["82103733"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Joint project of Chongqing Health Commission and Science and Technology Bureau","award":["2022QNXM048"],"award-info":[{"award-number":["2022QNXM048"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this study we aimed to investigate the prevalence of SARS-CoV-2 infection in psoriasis patients, and outcomes of SARS-CoV-2 infection and associated risk factors. A cross-sectional survey was conducted from February 2023 to March 2023. Information was obtained with online questionnaire about psoriasis patients on demographic characteristics, clinical characteristics, SARS-CoV-2 infection and outcomes, vaccination, and routine protection against COVID-19. Logistic regression analysis was used to explore risk factors with SARS-CoV-2 infection and exacerbation of psoriasis. A total of 613 participants were recruited. 516 (84.2%) were infected, and associated factors were sex, working status, routine protection against COVID-19, COVID-19 vaccination, impaired nail, infection exacerbate psoriasis, and severity of psoriasis. Among the patients infected with SARS-CoV-2, 30 (5.8%) required hospitalization, 122 (23.6%) had psoriasis exacerbation due to SARS-CoV-2 infection, and associated factors were subtype of psoriasis, discontinuation of psoriasis treatment during SARS-CoV-2 infection, response following COVID-19 vaccination, and severity of psoriasis. Booster dose vaccination contributed a low probability of COVID-19 sequelae. COVID-19 vaccine\u2019s effectiveness was unsatisfactory, while booster dose vaccination reduced the occurrence of COVID-19 sequelae in psoriasis patients of Southwest China. Patients treated with psoriasis shown to be safe, without a higher incidence of SARS-CoV-2 infection or COVID-19hospitalization compared to untreated patients. Stopping treatment during SARS-CoV-2 infection led to psoriasis exacerbation, so psoriasis treatment could be continued except severe adverse reaction.<\/jats:p>","DOI":"10.1038\/s41598-024-54424-y","type":"journal-article","created":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T17:03:24Z","timestamp":1710522204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence, outcomes and associated factors of SARS-CoV-2 infection in psoriasis patients of Southwest China: a cross-sectional survey"],"prefix":"10.1038","volume":"14","author":[{"given":"Yang","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai-Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shou-Min","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Zhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Xia","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Kun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,15]]},"reference":[{"key":"54424_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1056\/NEJMoa2001017","volume":"382","author":"N Zhu","year":"2020","unstructured":"Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727\u2013733 (2020).","journal-title":"N. Engl. J. Med."},{"key":"54424_CR2","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S2213-2600(22)00508-2","volume":"11","author":"T Burki","year":"2023","unstructured":"Burki, T. Moving away from zero COVID in China. Lancet Respir. Med. 11, 132 (2023).","journal-title":"Lancet Respir. Med."},{"key":"54424_CR3","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jiph.2022.11.024","volume":"16","author":"K Dhama","year":"2023","unstructured":"Dhama, K. et al. Global emerging Omicron variant of SARS-CoV-2: Impacts, challenges and strategies. J. Infect. Public Health 16, 4\u201314 (2023).","journal-title":"J. Infect. Public Health"},{"key":"54424_CR4","unstructured":"Notice on further optimization of the implementation of measures for the prevention and control of the COVID-19 epidemic. https:\/\/www.gov.cn\/xinwen\/2022-12\/07\/content_5730443.htm (last accessed: 7 December 2022)."},{"key":"54424_CR5","doi-asserted-by":"publisher","first-page":"e28616","DOI":"10.1002\/jmv.28616","volume":"95","author":"JM Chen","year":"2023","unstructured":"Chen, J. M. et al. Features and significance of the recent enormous COVID-19 epidemic in China. J. Med. Virol. 95, e28616 (2023).","journal-title":"J. Med. Virol."},{"key":"54424_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths, C. E. M., Armstrong, A. W., Gudjonsson, J. E. & Barker, J. Psoriasis. Lancet 397, 1301\u20131315 (2021).","journal-title":"Lancet"},{"key":"54424_CR7","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.jid.2018.01.039","volume":"138","author":"J Takeshita","year":"2018","unstructured":"Takeshita, J., Shin, D. B., Ogdie, A. & Gelfand, J. M. Risk of serious infection, opportunistic infection, and herpes zoster among patients with psoriasis in the United Kingdom. J. Invest. Dermatol. 138, 1726\u20131735 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"54424_CR8","doi-asserted-by":"publisher","first-page":"2161297","DOI":"10.1080\/09546634.2022.2161297","volume":"34","author":"KV Kwee","year":"2023","unstructured":"Kwee, K. V. et al. Prevalence, risk and severity of SARS-CoV-2 infections in psoriasis patients receiving conventional systemic, biologic or topical treatment during the COVID-19 pandemic: A cross-sectional cohort study (PsoCOVID). J. Dermatolog. Treat. 34, 2161297 (2023).","journal-title":"J. Dermatolog. Treat."},{"key":"54424_CR9","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/NEJMc2036242","volume":"384","author":"DM Skowronski","year":"2021","unstructured":"Skowronski, D. M. & De Serres, G. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 384, 1576\u20131577 (2021).","journal-title":"N. Engl. J. Med."},{"key":"54424_CR10","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1038\/s41467-023-37673-9","volume":"14","author":"Z Huang","year":"2023","unstructured":"Huang, Z. et al. Effectiveness of inactivated COVID-19 vaccines among older adults in Shanghai: Retrospective cohort study. Nat. Commun. 14, 2009 (2023).","journal-title":"Nat. Commun."},{"key":"54424_CR11","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.7326\/M21-1757","volume":"174","author":"P Deepak","year":"2021","unstructured":"Deepak, P. et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2: A prospective cohort study. Ann. Intern. Med. 174, 1572\u20131585 (2021).","journal-title":"Ann. Intern. Med."},{"key":"54424_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.it.2020.11.002","volume":"42","author":"P de Candia","year":"2021","unstructured":"de Candia, P., Prattichizzo, F., Garavelli, S. & Matarese, G. T cells: Warriors of SARS-CoV-2 infection. Trends Immunol. 42, 18\u201330 (2021).","journal-title":"Trends Immunol."},{"key":"54424_CR13","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon, A. & Sch\u00e4kel, K. Psoriasis pathogenesis and treatment. Int. J. Mol. Sci. 20, 1475 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"54424_CR14","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.3390\/ijms23136955","volume":"23","author":"S Zhou","year":"2022","unstructured":"Zhou, S. & Yao, Z. Roles of infection in psoriasis. Int. J. Mol. Sci. 23, 6955 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"54424_CR15","doi-asserted-by":"publisher","first-page":"e15113","DOI":"10.1111\/dth.15113","volume":"34","author":"K Aram","year":"2021","unstructured":"Aram, K., Patil, A., Goldust, M. & Rajabi, F. COVID-19 and exacerbation of dermatological diseases: A review of the available literature. Dermatol. Ther. 34, e15113 (2021).","journal-title":"Dermatol. Ther."},{"key":"54424_CR16","doi-asserted-by":"crossref","first-page":"204062232210993","DOI":"10.1177\/20406223221099333","volume":"13","author":"F Essien","year":"2022","unstructured":"Essien, F. et al. COVID-19-induced psoriatic arthritis: A case report. Ther. Adv. Chron. Dis. 13, 20406223221099332 (2022).","journal-title":"Ther. Adv. Chron. Dis."},{"key":"54424_CR17","unstructured":"China SARS-CoV-2 Infection Treatment Protocol (Trial 10th edition). http:\/\/www.nhc.gov.cn\/ylyjs\/pqt\/202301\/32de5b2ff9bf4eaa88e75bdf7223a65a\/files\/02ec13aadff048ffae227593a6363ee8.pdf (last accessed: 9 January 2023)."},{"key":"54424_CR18","doi-asserted-by":"publisher","first-page":"n1648","DOI":"10.1136\/bmj.n1648","volume":"374","author":"H Crook","year":"2021","unstructured":"Crook, H., Raza, S., Nowell, J., Young, M. & Edison, P. Long covid-mechanisms, risk factors, and management. BMJ 374, n1648 (2021).","journal-title":"BMJ"},{"key":"54424_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/S1473-3099(23)00112-3","volume":"23","author":"J Huang","year":"2023","unstructured":"Huang, J. et al. Infection rate in Guangzhou after easing the zero-COVID policy: Seroprevalence results to ORF8 antigen. Lancet Infect. Dis. 23, 403\u2013404 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"54424_CR20","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","volume":"49","author":"P Peduzzi","year":"1996","unstructured":"Peduzzi, P., Concato, J., Kemper, E., Holford, T. R. & Feinstein, A. R. A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 49, 1373\u20131379 (1996).","journal-title":"J. Clin. Epidemiol."},{"key":"54424_CR21","doi-asserted-by":"publisher","first-page":"6265","DOI":"10.2147\/JIR.S341429","volume":"14","author":"Q Wang","year":"2021","unstructured":"Wang, Q., Lv, C., Han, X., Shen, M. & Kuang, Y. A web-based survey on factors for unvaccination and adverse reactions of SARS-CoV-2 vaccines in Chinese patients with psoriasis. J. Inflamm. Res. 14, 6265\u20136273 (2021).","journal-title":"J. Inflamm. Res."},{"key":"54424_CR22","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41591-023-02212-y","volume":"29","author":"K Leung","year":"2022","unstructured":"Leung, K., Lau, E. H. Y., Wong, C. K. H., Leung, G. M. & Wu, J. T. Estimating the transmission dynamics of SARS-CoV-2 Omicron BF.7 in Beijing after adjustment of the zero-COVID policy in November-December 2022. Nat. Med. 29, 579\u2013582 (2022).","journal-title":"Nat. Med."},{"key":"54424_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s12016-022-08921-5","volume":"64","author":"JJ Zhang","year":"2023","unstructured":"Zhang, J. J., Dong, X., Liu, G. H. & Gao, Y. D. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin. Rev. Allergy Immunol. 64, 90\u2013107 (2023).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"54424_CR24","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11481-020-09974-z","volume":"16","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee, S. & Pahan, K. Is COVID-19 gender-sensitive?. J. Neuroimmune Pharmacol. 16, 38\u201347 (2021).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"54424_CR25","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2213-2600(20)30117-X","volume":"8","author":"H Cai","year":"2020","unstructured":"Cai, H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir. Med. 8, e20 (2020).","journal-title":"Lancet Respir. Med."},{"key":"54424_CR26","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1111\/1346-8138.15908","volume":"48","author":"F Long","year":"2021","unstructured":"Long, F. et al. Dermoscopic features of nail psoriasis: Positive correlation with the severity of psoriasis. J. Dermatol. 48, 894\u2013901 (2021).","journal-title":"J. Dermatol."},{"key":"54424_CR27","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1111\/jdv.15339","volume":"33","author":"E Christophers","year":"2019","unstructured":"Christophers, E. & van de Kerkhof, P. C. M. Severity, heterogeneity and systemic inflammation in psoriasis. J. Eur. Acad. Dermatol. Venereol. 33, 643\u2013647 (2019).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"1016\u20131035","key":"54424_CR28","first-page":"e1019","volume":"181","author":"CGK Ziegler","year":"2020","unstructured":"Ziegler, C. G. K. et al. SARS-CoV-2 receptor ACE2 is an interferon-stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues. Cell 181(1016\u20131035), e1019 (2020).","journal-title":"Cell"},{"key":"54424_CR29","doi-asserted-by":"publisher","first-page":"e28601","DOI":"10.1002\/jmv.28601","volume":"95","author":"F Branda","year":"2023","unstructured":"Branda, F., Scarpa, F., Ciccozzi, M. & Maruotti, A. Is a new COVID-19 wave coming from China due to an unknown variant of concern? Keep calm and look at the data. J. Med. Virol. 95, e28601 (2023).","journal-title":"J. Med. Virol."},{"key":"54424_CR30","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/d41586-021-02796-w","volume":"598","author":"S Mallapaty","year":"2021","unstructured":"Mallapaty, S. China\u2019s COVID vaccines have been crucial\u2014Now immunity is waning. Nature 598, 398\u2013399 (2021).","journal-title":"Nature"},{"key":"54424_CR31","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41586-020-2404-8","volume":"584","author":"S Hsiang","year":"2020","unstructured":"Hsiang, S. et al. The effect of large-scale anti-contagion policies on the COVID-19 pandemic. Nature 584, 262\u2013267 (2020).","journal-title":"Nature"},{"key":"54424_CR32","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1093\/cid\/ciac262","volume":"75","author":"S Gazit","year":"2022","unstructured":"Gazit, S. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naturally acquired immunity versus vaccine-induced immunity, reinfections versus breakthrough infections: A retrospective cohort study. Clin. Infect. Dis. 75, e545\u2013e551 (2022).","journal-title":"Clin. Infect. Dis."},{"key":"54424_CR33","doi-asserted-by":"publisher","first-page":"100702","DOI":"10.1016\/j.lanwpc.2023.100702","volume":"30","author":"The Lancet Regional Health-Western Pacific","year":"2023","unstructured":"The Lancet Regional Health-Western Pacific. The end of zero-COVID-19 policy is not the end of COVID-19 for China. Lancet Reg. Health West Pac. 30, 100702 (2023).","journal-title":"Lancet Reg. Health West Pac."},{"key":"54424_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s13671-022-00376-3","volume":"11","author":"SY Liew","year":"2022","unstructured":"Liew, S. Y., Tree, T., Smith, C. H. & Mahil, S. K. The impact of immune-modifying treatments for skin diseases on the immune response to COVID-19 vaccines: A narrative review. Curr. Dermatol. Rep. 11, 263\u2013288 (2022).","journal-title":"Curr. Dermatol. Rep."},{"key":"54424_CR35","first-page":"e13858","volume":"33","author":"OF Elmas","year":"2020","unstructured":"Elmas, O. F. et al. Psoriasis and COVID-19: A narrative review with treatment considerations. Dermatol. Ther. 33, e13858 (2020).","journal-title":"Dermatol. Ther."},{"key":"54424_CR36","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1111\/jocd.14381","volume":"20","author":"B Yalici-Armagan","year":"2021","unstructured":"Yalici-Armagan, B. et al. Treatment of psoriasis with biologics in the early COVID-19 pandemic: A study examining patient attitudes toward the treatment and disease course. J. Cosmet. Dermatol. 20, 3098\u20133102 (2021).","journal-title":"J. Cosmet. Dermatol."},{"key":"54424_CR37","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bjd.20963","volume":"186","author":"L Puig","year":"2022","unstructured":"Puig, L. et al. The biological basis of disease recurrence in psoriasis: A historical perspective and current models. Br. J. Dermatol. 186, 773\u2013781 (2022).","journal-title":"Br. J. Dermatol."},{"key":"54424_CR38","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40257-022-00721-z","volume":"23","author":"PC Wu","year":"2022","unstructured":"Wu, P. C. et al. New onset and exacerbations of psoriasis following COVID-19 vaccines: A systematic review. Am. J. Clin. Dermatol. 23, 775\u2013799 (2022).","journal-title":"Am. J. Clin. Dermatol."},{"key":"54424_CR39","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41586-020-2814-7","volume":"586","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses. Nature 586, 594\u2013599 (2020).","journal-title":"Nature"},{"key":"54424_CR40","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb, R. E. et al. Risk of serious infection with biologic and systemic treatment of psoriasis: Results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 151, 961\u2013969 (2015).","journal-title":"JAMA Dermatol."},{"key":"54424_CR41","doi-asserted-by":"publisher","first-page":"1046352","DOI":"10.3389\/fimmu.2022.1046352","volume":"13","author":"M Liu","year":"2022","unstructured":"Liu, M. et al. Risk of COVID-19 infection, hospitalization and mortality in psoriasis patients treated with interleukin-17 inhibitors: A systematic review and meta-analysis. Front Immunol. 13, 1046352 (2022).","journal-title":"Front Immunol."},{"key":"54424_CR42","doi-asserted-by":"publisher","first-page":"12422","DOI":"10.3390\/ijerph191912422","volume":"19","author":"P Gao","year":"2022","unstructured":"Gao, P., Liu, J. & Liu, M. Effect of COVID-19 vaccines on reducing the risk of long COVID in the real world: A systematic review and meta-analysis. Int. J. Environ. Res. Public Health 19, 12422 (2022).","journal-title":"Int. J. Environ. Res. Public Health"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54424-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54424-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54424-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T17:17:56Z","timestamp":1710523076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-54424-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,15]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["54424"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-54424-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,15]]},"assertion":[{"value":"4 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6331"}}